QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)
QQQ   413.98 (-2.23%)
AAPL   165.02 (-1.21%)
MSFT   399.23 (-1.25%)
META   480.34 (-4.28%)
GOOGL   153.88 (-1.37%)
AMZN   174.01 (-2.91%)
TSLA   147.25 (-1.79%)
NVDA   769.64 (-9.10%)
AMD   145.73 (-6.03%)
NIO   3.81 (-4.75%)
BABA   69.14 (+0.38%)
T   16.50 (+1.04%)
F   12.10 (+0.33%)
MU   106.14 (-5.17%)
GE   148.20 (-3.10%)
CGC   7.98 (+1.92%)
DIS   112.19 (-0.21%)
AMC   3.18 (+8.90%)
PFE   25.99 (+2.36%)
PYPL   61.89 (-0.34%)
XOM   119.99 (+1.24%)

Rite Aid cuts 95% of outstanding shares to hit NYSE minimum

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Rite Aid will chop its share count by about 95% in a bid to push the remaining shares above minimum trading requirements on the New York Stock Exchange.

The board of the struggling drugstore chain approved a 1-for-20 ratio for a reverse stock split after shareholders backed the plan last month. That will cut the total number of outstanding shares from nearly 1.1 billion, to about 54 million.

Rite Aid shares slid below $1 in December, prompting a removal warning from the NYSE. The drugstore chain said Wednesday after markets closed that on April 22, its shares will start trading on a split-adjusted basis.

The board approved the largest ratio out of three choices it had in the plan approved by shareholders. It also could have opted for consolidating 10 or 15 shares into one.

Shares closed at 57 cents on Wednesday but slipped early Thursday after the company said it lost $273 million in its fiscal fourth quarter and $422 million in the full year.

Rite Aid also said Thursday that it expects adjusted results for fiscal 2020 to range from a loss of a penny per share to earnings of 4 cents per share.

Analysts expect, on average, earnings of 2 cents per share, according to FactSet.

Rite Aid Corp., based in Camp Hill, Pennsylvania, runs 2,525 stores, mostly on the East and West coasts. It also operates a pharmacy benefit management business that runs prescription drug coverage for employers, insurers and other customers.

Rite Aid has struggled, like much larger competitors CVS Health and Walgreens, with reimbursement cuts and declining profitability from generic drugs. A relatively mild flu season also hasn't helped drugstore store sales this year.

Rite Aid also is in the middle of a big management shake-up. The company said last month that several top executives would leave, including long-time CEO John Standley. He plans to depart once his successor is appointed.

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Should you invest $1,000 in CVS Health right now?

Before you consider CVS Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CVS Health wasn't on the list.

While CVS Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Featured Articles and Offers

Search Headlines: